Neurology

Neurology focuses on disorders of the brain, spinal cord, and nervous system.

Alzheimer's Disease — amyloid plaques, tau tangles, cholinesterase inhibitors
Concussion — mild traumatic brain injury, coup-contrecoup, post-concussion syndrome, return-to-play
Epilepsy — seizure classification, antiepileptic drugs, surgical options
Migraine — cortical spreading depression, CGRP antibodies, triptans, gepants, magnesium/B2/CoQ10
Multiple Sclerosis — demyelination, McDonald criteria, disease-modifying therapies
Parkinson's Disease — dopamine depletion, levodopa, deep brain stimulation
ALS (Lou Gehrig's Disease) — motor neuron degeneration, riluzole, edaravone
Peripheral Neuropathy — nerve damage, diabetic neuropathy, pain management
Huntington's Disease — CAG repeat expansion, chorea, genetic testing
Myasthenia Gravis — neuromuscular junction, acetylcholine receptor antibodies, thymectomy
ME/CFS — post-exertional malaise, pacing, the under-recognized multisystem neuroimmune disease
POTS (postural orthostatic tachycardia syndrome) — full article plus 8 deep-dive guides on subtypes, tilt table test, salt & hydration, compression & exercise, medications, the POTS/MCAS/EDS triad, LDN, and vagus nerve & retraining
MCAS (mast cell activation syndrome) — full article plus 8 deep-dive guides on mediators & symptom map, testing, low-histamine diet, H1/H2 blocker stacks, cromolyn & ketotifen, triggers & flares, hereditary α-tryptasemia, and natural stabilizers

Neurology
Research Papers
Connections
Featured Videos

Key Research Papers

Foundational and recent peer-reviewed publications across the major neurology subspecialties — stroke, dementia, neurodegenerative disease, multiple sclerosis, epilepsy, headache, and movement disorders. Each citation links to the full text via DOI.

The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue Plasminogen Activator for Acute Ischemic Stroke. New England Journal of Medicine. 1995;333(24):1581–1587.
Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients with Acute Ischemic Stroke (AHA/ASA). Stroke. 2019;50(12):e344–e418.
Berkhemer OA, Fransen PSS, Beumer D, et al. A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke (MR CLEAN). New England Journal of Medicine. 2015;372(1):11–20.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation (RE-LY). New England Journal of Medicine. 2009;361(12):1139–1151.
Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation (ARISTOTLE). New England Journal of Medicine. 2011;365(11):981–992.
Sperling RA, Aisen PS, Beckett LA, et al. Toward Defining the Preclinical Stages of Alzheimer's Disease: Recommendations from the NIA-AA Workgroups on Diagnostic Guidelines for Alzheimer's Disease. Alzheimer's & Dementia. 2011;7(3):280–292.
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease (TRAILBLAZER-ALZ 2). JAMA. 2023;330(6):512–527.
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease (CLARITY-AD). New England Journal of Medicine. 2023;388(1):9–21.
Postuma RB, Berg D, Stern M, et al. MDS Clinical Diagnostic Criteria for Parkinson's Disease. Movement Disorders. 2015;30(12):1591–1601.
Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of Multiple Sclerosis: 2017 Revisions of the McDonald Criteria. Lancet Neurology. 2018;17(2):162–173.
Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis (OPERA I and II). New England Journal of Medicine. 2017;376(3):221–234.
Bensimon G, Lacomblez L, Meininger V. A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis. New England Journal of Medicine. 1994;330(9):585–591.
Brown RH Jr, Al-Chalabi A. Amyotrophic Lateral Sclerosis. New England Journal of Medicine. 2017;377(2):162–172.
Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE Official Report: A Practical Clinical Definition of Epilepsy. Epilepsia. 2014;55(4):475–482.
Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd Edition. Cephalalgia. 2018;38(1):1–211.
Goadsby PJ, Reuter U, Hallström Y, et al. A Controlled Trial of Erenumab for Episodic Migraine. New England Journal of Medicine. 2017;377(22):2123–2132.